Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
NCT06146985
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
67
Enrollment
OTHER
Sponsor class
Conditions
Thyroid Cancer
Interventions
COMBINATION_PRODUCT:
20 mg Famitinib & 1200 mg Adebrelimab
Sponsor
Ruijin Hospital